GlassScriptPhysician profile
Shaw Mahre
NPI 1053050237
$3,581.91
in general payments reported to CMS, 2019-2025
26 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.90 · 2023: $788 · 2024: $703 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734 · Travel and Lodging: $776 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.80 |
| Travel and Lodging | $776.21 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,211.98 | 2024-2025 | Interstim, Abre |
| Cvrx, INC. | $536.23 | 2023-2025 | Barostim Neo System |
| Smith+Nephew, INC. | $377.49 | 2023-2024 | Stravix, Grafix Pl, Stravix Pl |
| Sumitomo Pharma America, INC. | $260.69 | 2024-2025 | Gemtesa |
| Endologix LLC | $217.39 | 2023-2024 | Endocross Device, Torus Stent Graft System, Alto Abdominal Stent Graft System |
| Silk Road Medical, INC. | $184.92 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Bolton Medical INC | $166.93 | 2023-2024 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Boston Scientific Corporation | $147.36 | 2023-2025 | Spaceoar Vue System - 10ml, Eluvia, Ekosonic |
| Progenics Pharmaceuticals, INC. | $51.61 | 2024-2025 | |
| Coloplast Corp | $46.47 | 2025 | |
| Calyxo, INC. | $45.30 | 2025 | Cvac Aspiration System |
| Bard Peripheral Vascular, INC. | $35.90 | 2022 | |
| Procept Biorobotics Corporation | $33.51 | 2025 | |
| W. L. Gore & Associates, INC. | $31.57 | 2023 | Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Tag Thoracic Branch Endoprosthesis |
| Surmodics, INC. | $29.45 | 2024 | Pounce Thrombectomy System, Pounce Thrombectomy, Sublime 014 Rx Pta Balloon Dilatation Catheter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $22.74 | 2025 | Aveed, Xiaflex |
| Lemaitre Vascular, INC. | $22.37 | 2023 | Artegraft Vascular Graft |
| Laborie Medical Technologies Corp. | $21.82 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Kerecis Limited | $21.57 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Teleflex LLC | $19.47 | 2024 | Quikclot |
| Angiodynamics, INC. | $19.07 | 2024 | Auryon Laser System 100-120 Vac |
| Tactile Systems Technology INC | $18.82 | 2024 | Entre Plus, Flexitouch Plus |
| Acera Surgical, INC. | $16.36 | 2023 | Restrata Wound Matrix |
| Olympus America INC. | $14.83 | 2025 | Itind System |
| Solventum Corporation | $14.67 | 2024 | Promogran Prisma, Activ.A.C., Prevena |
| Sobi, INC | $13.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaw Mahre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.